Dr.ย Keunchilย Park
MD, PhD
Distinguished Chair Professor & Thoracic Oncologist
corporate_fareSamsung Medical Center, Seoul
Keunchil Park
MD, PhD
Prof. Keunchil Park is one of South Korea's most distinguished lung cancer specialists, with a career spanning over three decades in thoracic oncology, EGFR-targeted therapy, and precision cancer medicine. He is currently listed as Distinguished Chair Professor in the Department of Internal Medicine at Sungkyunkwan University, with a long-standing academic and clinical association with Samsung Medical Center in Seoul.
Prof. Park earned his MD, Master's, and PhD from Seoul National University College of Medicine, and subsequently undertook visiting research training at the National Cancer Institute in the United States. His clinical and research focus centres on EGFR-mutated non-small cell lung cancer, molecularly driven treatment strategies, and drug development for thoracic malignancies. He led the first genomic study of lung squamous cell carcinoma in an Asian population through the International Cancer Genome Consortium, and has contributed extensively to EGFR inhibitor trials and immunotherapy research. Sungkyunkwan University's research profile documents 643 research outputs, over 64,000 citations, and an h-index of 113, placing him among the most globally cited thoracic oncology researchers in Asia.
CancerFax can coordinate medical-record review and consultation support for international patients seeking an expert opinion in lung cancer or EGFR-mutated NSCLC, subject to hospital availability and case acceptance.
Why Consider Prof. Keunchil Park?
Prof. Park is internationally recognised for his expertise in EGFR-mutated non-small cell lung cancer, genomic profiling, and clinical trial-based treatment. He holds one of the most cited research records in Asian thoracic oncology.
Areas of Specialisation
Expert clinical and research focus in thoracic oncology and precision cancer medicine
Prof. Park's specialisation is centred on non-small cell lung cancer, with particular depth in EGFR-mutated disease and molecularly guided systemic therapy. His broader scope includes esophageal cancer and head and neck cancer.
EGFR-Targeted Therapy & Precision Oncology
Molecularly guided treatment for EGFR-mutated and other genomically defined lung cancers.
- arrow_rightTreatment planning for EGFR-mutated NSCLC across mutation subtypes
- arrow_rightFirst-, second-, and third-generation EGFR inhibitor strategies
- arrow_rightBiomarker-driven therapy selection based on comprehensive mutation profiling
- arrow_rightGenomic profiling to identify actionable mutations in lung cancer
- arrow_rightManagement of acquired resistance mechanisms following EGFR inhibitor therapy
- arrow_rightTreatment planning for EGFR exon 20 insertion-mutated NSCLC
Advanced Lung Cancer Management
Systemic treatment approaches for advanced and metastatic non-small cell and other thoracic malignancies.
- arrow_rightCheckpoint inhibitor therapy for eligible patients with advanced lung cancer
- arrow_rightResearch involvement in immunotherapy for lung squamous cell carcinoma
- arrow_rightAccess to investigational treatment programmes in thoracic oncology
- arrow_rightDrug development research involving novel targeted agents for lung cancer
Procedures Performed
Clinical services and treatment approaches in thoracic oncology
Prof. Park's clinical practice encompasses precision oncology, EGFR-directed systemic therapy, immunotherapy, and clinical trial enrolment for patients with lung cancer and selected other thoracic and upper gastrointestinal malignancies.
EGFR-Targeted Systemic Therapy
Targeted TherapyMolecularly guided treatment for EGFR-mutated non-small cell lung cancer, including selection and management of EGFR tyrosine kinase inhibitors across lines of therapy.
Medical Oncology โ Lung Cancer
Medical OncologyComprehensive systemic treatment for advanced and metastatic NSCLC and other thoracic malignancies, including chemotherapy and immunotherapy.
Clinical Trial & Drug Development Access
Complex DiseaseInvolvement in investigational treatment programmes for lung cancer, including novel targeted agents and drug development trials in thoracic oncology.
Second Opinion โ Lung Cancer
Second OpinionExpert review of lung cancer cases, particularly EGFR-mutated NSCLC, for patients seeking an independent opinion on diagnosis, molecular profiling, or treatment planning.
Research & Publications
Clinical research and peer-reviewed contributions in thoracic oncology
Prof. Keunchil Park has published extensively in lung cancer, with 643 research outputs, over 64,000 citations, and an h-index of 113 documented in Sungkyunkwan University's Pure research profile. His research has shaped precision treatment strategies for EGFR-mutated NSCLC and lung cancer genomics in Asian populations.
Prof. Park's full publication list is available on Sungkyunkwan University's research portal and PubMed. A curated summary can be prepared through CancerFax when coordinating a consultation.
Education & Training
Prof. Park completed his undergraduate medical training, postgraduate studies, and doctoral research at Seoul National University College of Medicine, one of South Korea's most prestigious medical institutions. He subsequently undertook visiting research training at the National Cancer Institute (NIH) in the United States.
Clinical Experience
Prof. Park has spent more than three decades in academic oncology at Samsung Medical Center and Sungkyunkwan University School of Medicine. He is currently listed as Distinguished Chair Professor in the Department of Internal Medicine at Sungkyunkwan University, and was previously documented by IASLC as Professor in the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center.
Languages & International
Prof. Park primarily consults in Korean. English is used in his international academic and research activities.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Korean-language practitioners at Samsung Medical Center.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Keunchil Park
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Keunchil Park's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Keunchil Park's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Keunchil Park before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Keunchil Park's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Keunchil Park's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Keunchil Park's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Keunchil Park
Prof. Park specialises primarily in lung cancer, with particular expertise in non-small cell lung cancer and EGFR-mutated NSCLC. His broader study focus also covers esophageal cancer and head and neck cancer, as documented by Sungkyunkwan University.
Prof. Park has a long-standing academic and clinical association with Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul. His current SKKU profile lists him as Distinguished Chair Professor in the Department of Internal Medicine. As a senior figure, current clinical appointment and active consultation availability should be confirmed directly with Samsung Medical Center before referral.
You can submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare a structured case summary, and coordinate with the hospital or doctor's team to explore the next steps, subject to availability and case acceptance at Samsung Medical Center.
Samsung Medical Center operates a dedicated International Healthcare Centre for overseas patients. CancerFax can assist with medical record review, case preparation, and coordination support for international patients seeking an expert opinion from Prof. Park, subject to hospital availability and case acceptance.
Prof. Park is internationally recognised for his research in EGFR-targeted therapy, precision oncology, and lung cancer genomics. He received the 2016 IASLC Merit Award for extraordinary contributions to the International Association for the Study of Lung Cancer, and led the first genomic study of lung squamous cell carcinoma in an Asian population through the International Cancer Genome Consortium.
Based on his extensive research profile and clinical focus on EGFR-mutated non-small cell lung cancer, Prof. Park may be well suited for second opinions on complex NSCLC cases, particularly those involving EGFR mutations, resistance to prior targeted therapy, or molecularly driven disease. Appointment and second-opinion availability should be confirmed through CancerFax before referral.
Connect with Keunchil Park Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.